β3-adrenergic receptors in pharmacotherapy of cardiovascular disorders Review article
Article Sidebar
Published:
Sep 30, 2011
Keywords:
β3-adrenergic receptors, cardiovascular disorders, β3-agonists
Main Article Content
Abstract
β-adrenergic system plays a pivotal role in regulation of cardiovascular functions. Apart from well know classic β1 and β2-receptors we also know β3-receptors. Originally β3-receptors were found to produce metabolic effects (lipolysis) and take part in thermoregulation due to their presence in white and brow adipose tissue. Further investigations discovered β3-receptors in other different tissues such as cardiac muscle and endothelium. In this article the authors presented potential benefits from introducing β3-receptors agonist into pharmacotherapy of cardiovascular disorders.
Article Details
How to Cite
Wsół, A., Światowiec , A., & Kuch , M. (2011). β3-adrenergic receptors in pharmacotherapy of cardiovascular disorders. Medycyna Faktow (J EBM), 4(3(12), 43-47. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2519
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Agabiti Rosei E., Rizzoni D.: Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67(8): 1097-107.
2. Ursino M.G., Vasina V., Raschi E. et al.: The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol. Res. 2009; 59(4): 221-34.
3. Pasini A.F., Garbin U., Stranieri C. et al.: Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am. J. Hypertens. 2008; 21(11): 1251-7.
4. Rozec B., Erfanian M., Laurent K. et al.: Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J. Am. Coll. Cardiol. 2009; 53(17): 1532-8.
5. Kampus P., Serg M., Kals J. et al.: Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57(6): 1122-8.
6. Espinola-Klein C., Weisser G., Jagodzinski A. et al.: β-blockers in Patients With Intermittent Claudication and Arterial Hypertension: Results From the Nebivolol or Metoprolol in Arterial Occlusive Disease Trial. Hypertension 2011; 58(2): 148-54.
2. Ursino M.G., Vasina V., Raschi E. et al.: The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol. Res. 2009; 59(4): 221-34.
3. Pasini A.F., Garbin U., Stranieri C. et al.: Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am. J. Hypertens. 2008; 21(11): 1251-7.
4. Rozec B., Erfanian M., Laurent K. et al.: Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J. Am. Coll. Cardiol. 2009; 53(17): 1532-8.
5. Kampus P., Serg M., Kals J. et al.: Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57(6): 1122-8.
6. Espinola-Klein C., Weisser G., Jagodzinski A. et al.: β-blockers in Patients With Intermittent Claudication and Arterial Hypertension: Results From the Nebivolol or Metoprolol in Arterial Occlusive Disease Trial. Hypertension 2011; 58(2): 148-54.